GLP1R and peripheral vascular disease: After five years of follow-up in patients with T2DM, the GLP-1 RAs and SGLT-2 inhibitors groups demonstrated significant reductions in mortality, CHD, HF, AF, stroke, peripheral vascular disease, and CKD, regardless which one of the drugs or its combination were used.